The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | B | Blood and blood forming organs | |
| 2 | B02 | Antihemorrhagics | |
| 3 | B02B | Vitamin K and other hemostatics | |
| 4 | B02BA | Vitamin K | |
| 5 | B02BA01 | Phytomenadione |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 20 mg |
| PAREN - Parenteral | 20 mg |
| Active Ingredient | Description | |
|---|---|---|
| Vitamin K1 |
The presence of vitamin K (i.e. vitamin K or substances with vitamin K activity) is essential for the formation within the body of prothrombin, factor VII, factor IX and factor X. Lack of vitamin K leads to an increased tendency to haemorrhage. When an antidote to an anticoagulant is necessary it is essential to use vitamin K1 itself, as vitamin K analogues are much less effective. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| KONAKION MM PAEDIATRIC Solution (ampoules) | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| KONAKION MM Solution (ampoules) | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
